Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs SOLAI Limited — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B), while SOLAI Limited trades at $3.72 (market cap $880.09M). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 28.7× SOLAI Limited's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 1 Days and SOLAI Limited for 40 Days on average.
| RPRX | SLAI | |
|---|---|---|
Market Cap | $25.27B | $880.09M |
Volume | 3,671,183 | 122,720 |
Sector | Health | Technology |
52-Week High | $63.96 | $21.63 |
52-Week Low | $35.44 | $2.74 |
Typical Hold Time | 1 Days | 40 Days |
Enterprise Value | $32.50B | $879.73M |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SLAI trades at $3.72 with no recent price movement. The stock shows a bullish technical signal despite concerning fundamentals, including negative profit margins (-134.76% net income margin) and declining revenue from $57M in 2022 to $23M in 2025. The company received a delisting notice from NYSE in July 2026, creating significant uncertainty. Cash flow remains negative at -$1.47M, though the P/B ratio of 0.35 suggests potential undervaluation based on book value.
Outlook remains highly speculative given delisting proceedings and persistent losses. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment. Investment opportunity exists only for risk-tolerant investors betting on turnaround potential, while major risks include delisting execution, continued cash burn, and competitive pressures in the AI infrastructure space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
